Share

    


Home / Search Results

Search Results

You searched for:

    Displaying results 1 - 20 of 80
  • 1
  • 2
  • 3
  • 4
  • »
Development of this comprehensive bispecific antibody program included policy development; toxicity management; creation of patient and staff education documents; creation of clinician tools like a toxicity scoring and charting tool and an electronic order set that segregates treatment options; and a monitoring system to safely transition patients from inpatient to outpatient care.
Explore the role of cardio-oncology in understanding and managing potential cardiovascular complications of immune checkpoint inhibitors.
ACCCBuzz recognizes June as Cancer Immunotherapy Month.
In this episode, CANCER BUZZ speaks with Brittney Baer, BSN, RN, patient care coordinator, immune effector cells, at Vanderbilt University Medical Center’s Vanderbilt-Ingram Cancer Center about key strategies and solutions to prioritize patient quality of life by addressing barriers to holistic survivorship care.
ACCC recently announced a collaboration with the Digital Medicine Society on a project to develop a risk prediction tool for cytokine release syndrome.
Advancements in clinical data and research have shown the immunotherapeutic potential of bispecific antibodies as treatment for hematologic cancers and solid tumors. In this episode, CANCER BUZZ speaks with Aaron Cumpston, PharmD, pharmacy clinical specialist in hematologic malignancies and bone marrow transplant and Christine Barrett, PharmD, BCOP, medical oncology clinical pharmacy specialist at …
As immune checkpoint inhibitors have become the standard of care for eligible patients with NSCLC, frequent monitoring of irAEs as well as provider and patient education on the signs and symptoms of pneumonitis can ensure improved clinical outcomes for patients.
Managing immunotherapy related adverse events (irAEs) requires a team-based effort, with pharmacists playing an integral role in their identification and management within both outpatient and inpatient multidisciplinary teams.
June is Cancer Immunotherapy Month, and ACCC is highlighting the important work that it and its partners are doing to increase patient access to these novel therapies.
January 19, 2023
ACCC is presenting a town hall webinar through our Immuno-oncology Institute on Thursday, January 19, at 2 pm. This live event will focus on multidisciplinary education surrounding TILs, with a strong focus on the importance of implementing clinical trials in the community setting. The webinar will provide an opportunity to feature didactic presentations, a panel discussion, and live Q&A from audience …
The first post in ACCC's "Subspeciality Immuno-Oncology Insights" series—the APP perspective and real-world strategies for tackling current challenges in the delivery of immunotherapies for cancer.
Dr. Sanjay Juneja explores how—with many cancers now being treated like a chronic disease—it may be time to cancel the term “a cure for cancer.”
Learn how ACCC's bispecific antibody initiative “Best Practices in Expanding Access to Bispecific Antibodies and Adverse Event Management”—developed in partnership with the Society for Immunotherapy of Cancer—will help expand the use of these novel therapies and optimize care for patients with cancer.
In recognizing Cancer Immunotherapy Month and National Cancer Survivors Day (June 5), ACCC is highlighting the resources it has created to assist the multidisciplinary team in creating and adapting survivorship care plans to meet these patients’ unique needs and support toxicity management for better outcomes.
In this episode, hear from two experts in cancer immunotherapy on the exciting potential of TIL Cell Therapy in melanoma and beyond.
This article explores Johns Hopkins University’s unique approach to recruiting specialists outside the field of oncology to participate in its virtual immune-related Toxicity Team.
Presented at the 63rd ASH Annual Meeting, December 11-14, 2021, in Atlanta, GA.
Learn the 10 feasible and impactful “how-tos” Summit participants identified within three domains—care coordination and communication, clinical trials, and acknowledging and mitigating implicit bias.
While the number of oncology patients and survivors is increasing, the growth of medical oncologists has lagged behind, and advanced practice providers (APPs) play a critical role in filling this care gap.
In addition to the global pandemic, ongoing lawsuits from referenced biologics' manufacturers suing biosimilar manufacturers are having a negative impact on the development and approval of new biosimilars.
    Displaying results 1 - 20 of 80
  • 1
  • 2
  • 3
  • 4
  • »